Atovaquone - Warnings and Precautions
The following warnings and precautions are taken directly from the US FDA-approved drug label for Atovaquone. This is the same information dispensing pharmacists read.
5 WARNINGS AND PRECAUTIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Limited Oral Absorption Absorption of orally administered atovaquone oral suspension is limited but can be significantly increased when the drug is taken with food.
Failure to administer atovaquone oral suspension with food may result in lower plasma atovaquone concentrations and may limit response to therapy.
Consider therapy with other agents in patients who have difficulty taking atovaquone oral suspension with food or in patients who have gastrointestinal disorders that may limit absorption of oral medications [see Clinical Pharmacology (Section 12.3)].
5.2 Hepatotoxicity Cases of cholestatic hepatitis, elevated liver enzymes, and fatal liver failure have been reported in patients treated with atovaquone [see Adverse Reactions (Section 6.2)].
If treating patients with severe hepatic impairment, closely monitor patients following administration of atovaquone oral suspension. -------------- WARNINGS AND PRECAUTIONS ----------------- Failure to administer atovaquone oral suspension with food may result in lower plasma atovaquone concentrations and may limit response to therapy.
Patients with gastrointestinal disorders may have limited absorption resulting in suboptimal atovaquone concentrations.
Hepatotoxicity: Elevated liver chemistry tests and cases of hepatitis and fatal liver failure have been reported.
5.1 Risk of Limited Oral Absorption Absorption of orally administered atovaquone oral suspension is limited but can be significantly increased when the drug is taken with food.
Failure to administer atovaquone oral suspension with food may result in lower plasma atovaquone concentrations and may limit response to therapy.
Consider therapy with other agents in patients who have difficulty taking atovaquone oral suspension with food or in patients who have gastrointestinal disorders that may limit absorption of oral medications [see Clinical Pharmacology ].
5.2 Hepatotoxicity Cases of cholestatic hepatitis, elevated liver enzymes, and fatal liver failure have been reported in patients treated with atovaquone [see Adverse Reactions ].
If treating patients with severe hepatic impairment, closely monitor patients following administration of atovaquone oral suspension.
Applies to YOU?
Some warnings apply only to specific age groups, health conditions, or other medicines. Ask GoDavaii AI to filter which of these 12+ warnings apply to your profile.
Ask Health AI \u2192